AstraZeneca Reports 4-Year Follow-Up Data for Imfinzi and Imjudo in P-III Trial for the Treatment of Hepatocellular Carcinoma
Shots:
- The P-III (HIMALAYA) clinical trial evaluates the safety & efficacy of Imjudo (300mg) + Imfinzi (1500, q4w) vs sorafenib in unresectable HCC patients (n=1324) with no prior systemic therapy
- For patients being treated with Imjudo + Imfinzi (STRIDE regimen), results demonstrated a m-OS of 16.4mos. vs 13.8mos for sorafenib, OS rate at 36mos. of 30.7% vs 19.8% & OS rate at 48mos. of 25.2% vs 15.1%
- The 4-year follow-up data depicted that a single priming dose of STRIDE regimen reduced the risk of death by 22% vs sorafenib as out of the patients treated with the STRIDE regimen, 25.2% were alive at 4yrs. vs 15.1% for sorafenib
Ref: Businesswire | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
